The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
Recent advances have seen immuno-therapy become a shining light within oncology research, transforming both the way cancer treatments are viewed and the potential standards of care and outcomes.
On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.
In February 2015, Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men